Crossmark

Insulin-like growth factor 2 (IGF2) expression in adrenocortical disease due to PRKAR1A mutations compared to other benign adrenal tumors

Published Online: 2021-01-09

Published Print: 2021-06

Authors

Nadella, Kiran S.

Berthon, Annabel

Almeida, Madson Q.

Levy, Isaac

Faucz, Fabio R. https://orcid.org/0000-0001-7959-9842
Stratakis, Constantine A.
License Information

Text and Data Mining valid from 2021-01-09

Version of Record valid from 2021-01-09
More Information

Article History

Received: 31 May 2020

Accepted: 1 December 2020

First Online: 9 January 2021

Compliance with ethical standards

:

: C.A.S. holds patent on the PRKAR1A, PDE11A, and GPR101 genes and/or their function and his laboratory has received research funding from Pfizer Inc. F.R.F holds patent on the GPR101 gene and/or its function. The other authors have nothing to disclose.

: Ethics approval for the study protocols 1995-CH-0059 and 2000-CH-0160 was obtained from the Institutional Review Board (IRB) in the NIH Office of Intramural Research

: Informed written consent was obtained from all subjects.

Document is current